14-06-2018
Hailshadow / iStockphoto.com
The Patent Trial and Appeal Board (PTAB) has now rejected challenges to six patents owned by Gilead covering the company’s hepatitis C medicines.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Initiative for Medicines, Access & Knowledge, I-MAK, patent, Sovaldi, Gilead, generics, hepatitis C, pharmaceuticals, PTAB
PTAB blocks Qiagen’s bid to invalidate diagnostics patent
20-07-2020
PTAB shoots down tenth I-MAK Gilead challenge
24-07-2018
MSF challenges Gilead patent in China
20-06-2018
Non-profit group continues battle against Gilead patents
08-12-2017
Public interest group challenges ‘unmerited’ Gilead patents
26-10-2017
